Division of Hematology-Oncology, Department of Pediatrics, University of Utah School of Medicine and Primary Children's Medical Center, Salt Lake City, Utah, USA.
Pediatr Blood Cancer. 2011 Jul 1;56(7):1026-31. doi: 10.1002/pbc.22757. Epub 2010 Sep 16.
Central nervous system (CNS) atypical teratoid/rhabdoid tumors (AT/RT) are aggressive tumors usually diagnosed in young children and characterized by SMARCB1 (INI1, hSNF5) gene abnormalities. Despite initial chemo-radiation responsiveness, most children die of progressive disease (PD). Little data regarding familial AT/RT clinical course exist. This study described and compared familial (F) versus sporadic (S) AT/RT and elucidated SMARCB1 mutations and inheritance patterns.
A retrospective chart review, pedigree, and SMARCB1 analysis were done.
Between January 1989 and June 2009, 20 children with CNS AT/RT were diagnosed, 8-S and 12-F. Median age at diagnosis (months) of S and F patient were: 13 and 4.8, respectively. Median survival (months) was S-21, F4.5, and 8-all. Pedigree analyses showed unaffected parent carriers with multiple affected offspring.
Children with F-AT/RT are younger, have more extensive disease, and are more likely to die from PD than children with S-AT/RT. Surgery, radiation, and chemotherapy were important in achieving long-term survival. Pedigree analysis supports autosomal dominant inheritance pattern with incomplete penetrance. Germline SMARCB1 mutation analysis is important in all patients diagnosed with AT/RT to (1) determine actual incidence of F-AT/RT, (2) determine penetrance of predisposing mutations, (3) provide appropriate genetic counseling, and (4) establish surveillance screening guidelines.
中枢神经系统(CNS)非典型畸胎样/横纹肌样肿瘤(AT/RT)是一种侵袭性肿瘤,通常在幼儿中诊断出,其特征是 SMARCB1(INI1,hSNF5)基因异常。尽管初始化疗和放疗有反应,但大多数患儿死于进行性疾病(PD)。关于家族性 AT/RT 临床病程的数据很少。本研究描述并比较了家族性(F)与散发性(S)AT/RT,并阐明了 SMARCB1 突变和遗传模式。
进行了回顾性图表审查、家族史和 SMARCB1 分析。
1989 年 1 月至 2009 年 6 月期间,诊断出 20 例 CNS AT/RT 患儿,其中 8 例为 S 型,12 例为 F 型。S 型和 F 型患儿的诊断时中位年龄(月)分别为 13 和 4.8。S 型患儿的中位生存期(月)为 21,F 型为 4.5,所有患儿为 8。家族史分析显示,无明显病变的父母为携带者,且多个子女受累。
与 S-AT/RT 患儿相比,F-AT/RT 患儿年龄更小,疾病更广泛,更有可能死于 PD。手术、放疗和化疗对于实现长期生存非常重要。家族史分析支持常染色体显性遗传模式,存在不完全外显率。对所有诊断为 AT/RT 的患者进行种系 SMARCB1 突变分析非常重要,(1)确定 F-AT/RT 的实际发生率,(2)确定易感突变的外显率,(3)提供适当的遗传咨询,(4)制定监测筛查指南。